Survodutide
Adults without diabetes · SubQ · 2024 phase 2 obesity trial
SubQ target-dose arms from the 46-week obesity trial, with the study’s escalation and maintenance periods kept distinct.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| STUDY ARM | Dose | Frequency | Context |
|---|---|---|---|
| 0.6 mg target arm | 0.6 mg | Once weekly | Source |
| 2.4 mg target arm | 2.4 mg | Once weekly | Source |
| 3.6 mg target arm | 3.6 mg | Once weekly | Source |
| 4.8 mg target arm | 4.8 mg | Once weekly | Source |
The four targets were assigned to different groups. The table does not reproduce the 20-week escalation schedule.
Escalation is part of the protocol
The trial enrolled 387 adults without diabetes and used 20 weeks of escalation followed by 26 weeks of maintenance.
Keep indications separate
These are obesity-trial targets. They should not be substituted for protocols studying liver disease or interpreted as four consecutive titration steps.
Download the chart
Further reading
Survodutide monograph on myPeptides
References
Do the four rows form one escalation plan?
No. Each target belongs to a different study group. The trial used a separate 20-week escalation phase.